O2TODAY

O2TODAY and SINTX Technologies Enter Commercialization Agreement to Fight COVID-19

Retrieved on: 
Thursday, February 25, 2021

Since the outbreak of COVID-19, SINTX Technologies has been testing the antiviral properties of silicon nitride for use in antipathogenic applications.

Key Points: 
  • Since the outbreak of COVID-19, SINTX Technologies has been testing the antiviral properties of silicon nitride for use in antipathogenic applications.
  • O2TODAY and SINTX entered a collaboration during 2020 shortly after the COVID-19 pandemic was underway.
  • The agreement includes a license fee, a commercial agreement on silicon nitride sales, and royalties based upon product sales of the masks and filters.
  • We are thrilled to enter this agreement with SINTX Technologies, a company that has a remarkable history of conducting the science and developing products based on silicon nitride and its various formulations, said Bruce Lorange, CEO of O2TODAY.

O2TODAY Announces Agreement to Develop Antimicrobial Face Masks with SINTX Technologies, Inc. to Help Prevent Spread of COVID-19 and Other Viral Diseases

Retrieved on: 
Tuesday, August 4, 2020
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200804005378/en/
    One of the mask styles O2TODAY and SINTX plan to develop research upon.
  • O2TODAY and SINTX plan to jointly fund collaborative research and product development activities in Salt Lake City, Utah, with the input of external laboratories as well.
  • Upon the joint development of an antimicrobial mask, the companies will enter a commercialization agreement under which O2TODAY will be the exclusive global distributor for face masks & replacement filters containing SINTXs silicon nitride.
  • The collaboration with SINTX is intended to develop and bring to market a much-needed product in the fight against COVID-19.